Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GRN | P28799 | 1/20 | 0.31 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17198879 | 0.81 | HTT (0.38) | — | |
| SCHEMBL17035448 | 0.78 | KDM4E (0.31) | KDM4EGRNSORT1HRH4 | |
| SCHEMBL21718607 | 0.76 | DPP4 (0.31) | — | |
| SCHEMBL21719993 | 0.76 | — | — | |
| SCHEMBL21718608 | 0.76 | HRH4 (0.40) | HRH4 | |
| SCHEMBL10064768 | 0.76 | HTT (0.31) | — | |
| SCHEMBL15192767 | 0.76 | MAP3K14 (0.35) | — | |
| SCHEMBL12157416 | 0.76 | BRD4 (0.35) | KDM4EGRNSORT1 | |
| SCHEMBL14050196 | 0.74 | PTGS1 (0.39) | KDM4ETDP1 | |
| SCHEMBL8688306 | 0.73 | CYP3A4 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4289427-A1 | DIHYDRO[1,8]NAPHTHYRIDIN-7-ONE AND PYRIDO[3,2-B][1,4]OXAZIN-3-ONE FOR USE IN TREATING CANCER, AND METASTASES IN PARTICULAR. | Anagenesis Biotechnologies (FR) | 2023-12-13 | — | — | EP | disclosed |
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230339970-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| US-20230322853-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE DISEASES AND DISORDERS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-10-12 | — | — | US | disclosed |
| US-11752155-B2 | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2023-09-12 | — | — | US | disclosed |
| WO-2023154519-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20230234949-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2023-07-27 | — | — | US | disclosed |
| US-20230234949-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2023-07-27 | — | — | US | disclosed |
| US-20130109656-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. | 2013-05-02 | — | — | US | disclosed |
| US-8309685-B2 | HCV protease inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8268871-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120196845-A1 | QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2012-08-02 | — | — | US | disclosed |
| US-20120010414-A1 | GLYCINE TRANSPORTER INHIBITING SUBSTANCES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-12 | — | — | US | disclosed |
| US-20120010414-A1 | GLYCINE TRANSPORTER INHIBITING SUBSTANCES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-12 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20100331283-A1 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-7795282-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | ABCG2, CYP3A43, CYP3A5 | KDM4E 3792/4885TDP1 2415/4885GRN 1182/4885 |
| US-20230322853-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE DISEASES AND DISORDERS | POLI, PCNA, POLH | KDM4E 1554/4885TDP1 239/4885GRN 149/4885 |
| US-20130109656-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIFC1 | KDM4E 939/4885TDP1 179/4885GRN 2938/4885 |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | EP300, KAT2A, KAT6A | KDM4E 167/4885TDP1 1085/4885GRN 2645/4885 |
| US-20230234949-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | MAP1B, RRP12, MYT1 | KDM4E 1144/4885TDP1 1092/4885GRN 829/4885 |
| US-20120010414-A1 | GLYCINE TRANSPORTER INHIBITING SUBSTANCES | SLC18A2, SLC1A2, SLC6A1 | KDM4E 4384/4885TDP1 1612/4885GRN 148/4885 |
| US-20230339970-A1 | CASEIN KINASE 1 DELTA MODULATORS | CSNK1D, CSNK1A1, CSNK1G1 | KDM4E 2194/4885TDP1 1274/4885GRN 3056/4885 |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | KDM4E 2333/4885TDP1 910/4885GRN 513/4885 |
| US-20120196845-A1 | QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, CHRNA5 | KDM4E 1962/4885TDP1 2391/4885GRN 2528/4885 |
| US-11820773-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | KDM4E 4358/4885TDP1 2353/4885GRN 235/4885 |
| US-20100331283-A1 | Mitotic kinesin inhibitors and methods of use thereof | KIF5B, KIF2C, KIFC1 | KDM4E 939/4885TDP1 179/4885GRN 2938/4885 |
| US-11752155-B2 | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders | GRIN2A, GRIN1, GRIN2B | KDM4E 2211/4885TDP1 3564/4885GRN 1553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.